Lantern Isotopes
Lantern Production Line Two
Fixed-rate notes on medical isotope production. No reactor, no fuel, and a customer base that cannot substitute.
Molybdenum-99 decays into the technetium-99m used in roughly forty million diagnostic scans a year, and it has historically come from a handful of aging research reactors, two of which have gone offline unexpectedly and caused global shortages. Accelerator production needs no reactor and no fissile fuel, and its output has a 66-hour half-life, which means the product cannot be stockpiled and customers cannot switch suppliers on short notice. Line one is in commercial operation; this funds line two.
$12,240,000 committed of $18,000,000
$11,016,000 released · 68% subscribed
- Minimum
- $500
- Target coupon
- 6.15%
- Term
- 6 yr
- Investors
- 2,483
$100 per unit
Annual, fixed
Closes February 26, 2027 · 166 days remaining
Sign in to see your limit
- Eligibility depends on residency, accreditation status and how much you have already invested this year.
- You can read everything about this offering without an account. Committing capital requires one.
Demo · viewing as
Browsing without an account. Everything is visible; nothing is purchasable until you verify who and where you are.
Or answer the questions yourselfNo money will move
No payment processor is connected. The commitment flow runs end to end, through amount, agreement, signature and receipt, and records a simulated position rather than a charge.
Capital release schedule
1 of 2 rungs released
Release is structured as staged closings rather than withheld proceeds. Amounts shown are cumulative against the $12.2M committed to this offering.
Line one sustained commercial production
Capital released- TRL target
- TRL 8
- Cumulative release
- 90% · $11,016,000
- Certified
- April 2, 2026
Verified by: Batch release records; distributor acceptance across twelve months
Certifier: Thornbury Technical Certification
Line two qualified and releasing product
Pending- TRL target
- TRL 9
- Cumulative release
- 100% · $12,240,000
- Target
- September 30, 2027
Verified by: Quality system approval for line two; first commercial batch released
Held by the escrow agent on subscription
90% of committed capital
Unlocks on the next certification
Escrow agent: Meridian Trust, N.A.. Certification is performed by an independent party with no economic interest in the release.